From 01 Mar, Botox (botulinum
toxin type A) will be listed on the
Pharmaceutical Benefits Scheme
(PBS) for the prophylaxis of
headaches in adults with chronic
migraine.
The listing is restricted to those
who experience headaches for 15
days or more per month with a
migraine on at least eight of those
days.
The treatment will be
administered by trained
neurologists.The above article was sent to subscribers in Pharmacy Daily's issue from 03 Mar 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Mar 14
AUSTRALIA needs more pharmacists than ever, in the face of an ageing population and rising healthcare demands, according to the Pharmaceutical Society of Australia (PSA).
INTERN pharmacists from Monash University are set to join Victoria’s immunisation workforce under a new Secretary Approval by the Victorian Health Department.
VIRTUAL care delivered through telephone or video conference has now embedded itself as a core component of healthcare delivery in NSW, new market reports released today have revealed.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.